
Cambridge Healthtech Institute’s 3rd Annual
Targeting PPIs with Peptides & Small Molecules
Therapeutic Options for Protein-Protein Interaction Drug Targets
11 - 12 November 2026 ALL TIMES CET+1
Protein-Protein Interactions (PPIs) represent a large percentage of drug targets because many diseases can be traced to protein complexes that either fall apart too easily or stay together too long. However, many disease-related PPIs are challenging to drug because they are intracellular and therefore can only be targeted by cell-permeable therapeutic agents. Typically, only small molecules can freely pass across the cell membrane; most peptides and antibodies are too large. But alas, PPI surfaces are often too featureless, large and non-enzymatic for small molecules to be revealed by traditional high-throughput screening. However, new biophysical-based methods and other discovery advances are enabling small molecule success against PPIs. Furthermore, recent innovations in peptide chemistry and applications of artificial intelligence (AI)/machine learning (ML) are enabling the discovery or design of cell-penetrable and/or orally bioavailable peptides. Join Cambridge Healthtech Institute’s Targeting PPIs with Peptides & Small Molecules conference to hear case studies on PPI-targeted agents and learn about the innovations driving progress.